Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) announced the closing of its non-brokered private placement on September 29, 2026, raising aggregate gross proceeds of $1,598,144.70. The Calgary-based biotechnology company issued 10,654,298 units at $0.15 per unit, each consisting of one common share and one warrant. Proceeds are earmarked primarily for a deposit on phase 1 clinical trials for the company's lead compound MB-204, a novel adenosine A2a antagonist targeting neurological disorders.

Key Points

  • Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) closed its non-brokered private placement on September 29, 2026
  • The company raised $1,598,144.70 gross by issuing 10,654,298 units at $0.15 each, with each unit including one warrant exercisable at $0.20
  • Net proceeds will fund a phase 1 clinical trial deposit for MB-204, general and administrative expenses, and working capital
  • Investors may be watching warrant acceleration terms and progress toward MB-204 clinical trial milestones

Private Placement Structure and Warrant Terms for MRVL Shareholders

Each unit issued under the offering comprises one common share and one warrant entitling the holder to purchase an additional common share at $0.20, commencing on the 61st day after closing and valid for one year from the closing date. The release states the company may accelerate warrant expiry if the volume weighted average trading price on the TSX Venture Exchange reaches at least $0.25 per share for five consecutive trading days, with not less than 30 days' notice provided to warrant holders. Units issued under the listed issuer financing exemption are not subject to a statutory hold period under Canadian securities laws.

Finders' Fees and Participating Brokers in the Marvel Biosciences Offering

In connection with the offering, Marvel Biosciences paid $77,175.49 in cash commissions and issued 494,737 finder's warrants to participating finders. Raymond James Ltd., Canaccord Genuity Corp., Research Capital Corporation, Acumen Capital Finance Partners Limited, Hampton Securities, and Leede Financial Inc. acted as finders in the transaction, the disclosure states. The company did not disclose the exercise price or terms of the finder's warrants beyond their issuance in the announcement.

MB-204 Clinical Advancement and Use of Proceeds

Marvel Biosciences is developing MB-204, described as a novel fluorinated derivative of Istradefylline, the only clinically approved adenosine A2a antagonist, with potential application in neurological conditions including autism, depression, Alzheimer's disease, Rett Syndrome, and Fragile X Syndrome. The company states net proceeds from the offering will be directed toward a deposit for phase 1 clinical trials for MB-204, alongside general and administrative expenses and working capital. The immediate share price impact was not clear from available public information.